1: Changphasuk P, Inpad C, Horpaopan S, Khunchai S, Phimsen S, Surangkul D, Janvilisri T, Silsirivanit A, Kaewkong W. SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting BIN1, MCL-1 and BCL2 Splicing Errors and Enabling Apoptosis of Cholangiocarcinoma Cells. Front Biosci (Schol Ed). 2024 Sep 29;16(3):17. doi: 10.31083/j.fbs1603017. PMID: 39344395.
2: Li X, Nakashima K, Ito M, Matsuda M, Chida T, Sekihara K, Takahashi H, Kato T, Sawasaki T, Suzuki T. SRPKIN-1 as an inhibitor against hepatitis B virus blocking the viral particle formation and the early step of the viral infection. Antiviral Res. 2023 Dec;220:105756. doi: 10.1016/j.antiviral.2023.105756. Epub 2023 Nov 20. PMID: 37992764.
3: Wahid M, Pratoomthai B, Egbuniwe IU, Evans HR, Babaei-Jadidi R, Amartey JO, Erdelyi V, Yacqub-Usman K, Jackson AM, Morris JC, Patel PM, Bates DO. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion. Cancer Immunol Immunother. 2023 Dec;72(12):4001-4014. doi: 10.1007/s00262-023-03534-z. Epub 2023 Nov 16. PMID: 37973660; PMCID: PMC10700477.
4: He C, Liu B, Wang HY, Wu L, Zhao G, Huang C, Liu Y, Shan B, Liu L. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic- sensitizing effects on extranodal NK/T-cell lymphoma cells. BMC Cancer. 2022 Oct 27;22(1):1100. doi: 10.1186/s12885-022-10158-6. PMID: 36303126; PMCID: PMC9609466.
5: Gu YY, Tan XH, Song WP, Song WD, Yuan YM, Xin ZC, Wang JD, Fang D, Guan RL. Icariside Ⅱ Attenuates Palmitic Acid-Induced Endothelial Dysfunction Through SRPK1-Akt-eNOS Signaling Pathway. Front Pharmacol. 2022 Jun 30;13:920601. doi: 10.3389/fphar.2022.920601. PMID: 35846993; PMCID: PMC9280058.
6: Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicol In Vitro. 2022 Aug;82:105385. doi: 10.1016/j.tiv.2022.105385. Epub 2022 May 11. PMID: 35568131.
7: Pogacar Z, Groot K, Jochems F, Dos Santos Dias M, Mulero-Sánchez A, Morris B, Roosen M, Wardak L, De Conti G, Velds A, Lieftink C, Thijssen B, Beijersbergen RL, Bernards R, Leite de Oliveira R. Genetic and compound screens uncover factors modulating cancer cell response to indisulam. Life Sci Alliance. 2022 May 9;5(9):e202101348. doi: 10.26508/lsa.202101348. PMID: 35534224; PMCID: PMC9095732.
8: Malhi NK, Allen CL, Stewart E, Horton KL, Riu F, Batson J, Amoaku W, Morris JC, Arkill KP, Bates DO. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy. Am J Physiol Heart Circ Physiol. 2022 Jun 1;322(6):H1014-H1027. doi: 10.1152/ajpheart.00001.2022. Epub 2022 Mar 18. PMID: 35302878; PMCID: PMC9109797.